Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 3/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13962958 | 1.00 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1TAAR1DPP4 | |
| SCHEMBL28379986 | 0.81 | TAAR1 (0.44) | SLC1A3SLC1A2SLC1A1TAAR1DPP4 | |
| SCHEMBL19812644 | 0.75 | TAAR1 (0.47) | SLC1A3SLC1A2SLC1A1TAAR1DPP4 | |
| SCHEMBL4135682 | 0.74 | — | — | |
| SCHEMBL28905950 | 0.74 | — | — | |
| SCHEMBL14478277 | 0.74 | — | — | |
| SCHEMBL1696681 | 0.73 | TAAR1 (0.44) | SLC1A3SLC1A2SLC1A1TAAR1DPP4 | |
| SCHEMBL1696682 | 0.73 | TAAR1 (0.44) | SLC1A3SLC1A2SLC1A1TAAR1DPP4 | |
| SCHEMBL15203049 | 0.73 | OPRM1 (0.40) | SLC1A3SLC1A2SLC1A1TAAR1MME | |
| SCHEMBL22086282 | 0.73 | OPRM1 (0.40) | SLC1A3SLC1A2SLC1A1TAAR1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585482-B1 | GLUCAGON ANALOGUES | ZEALAND PHARMA AS (DK) | 2019-03-27 | — | — | EP | claimed |
| US-20150376257-A1 | GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2015-12-31 | — | — | US | claimed |
| US-20130157929-A1 | GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2013-06-20 | — | — | US | claimed |
| EP-2585482-A1 | GLUCAGON ANALOGUES | Zealand Pharma A/S (DK) | 2013-05-01 | — | — | EP | claimed |
| WO-2011160633-A1 | GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2011-12-29 | — | — | WO | claimed |
| EP-2585482-B1 | GLUCAGON ANALOGUES | ZEALAND PHARMA AS (DK) | 2019-03-27 | — | — | EP | disclosed |
| WO-2016154058-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| EP-2525809-B1 | GLUCAGON-GLP1 DUAL AGONISTS FOR USE IN THE TREATMENT OF CARDIAC CONDITIONS | ZEALAND PHARMA AS (DK) | 2016-08-03 | — | — | EP | disclosed |
| US-20150376257-A1 | GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2015-12-31 | — | — | US | disclosed |
| US-9169310-B2 | Glucagon analogues | ZEALAND PHARMA A/S (DK) | 2015-10-27 | — | — | US | disclosed |
| WO-2013123266-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20130157953-A1 | TREATMENT OF CARDIAC CONDITIONS | ZEALAND PHARMA A/S (DK) | 2013-06-20 | — | — | US | disclosed |
| US-20130157929-A1 | GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2013-06-20 | — | — | US | disclosed |
| EP-2585482-A1 | GLUCAGON ANALOGUES | Zealand Pharma A/S (DK) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011160633-A1 | GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011088837-A1 | TREATMENT OF CARDIAC CONDITIONS | ZEALAND PHARMA A/S (DK) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376257-A1 | GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | SLC1A3 2769/4885SLC1A2 4014/4885SLC1A1 3560/4885 |
| US-20130157953-A1 | TREATMENT OF CARDIAC CONDITIONS | GLP1R, GCGR, TNNT2 | SLC1A3 619/4885SLC1A2 583/4885SLC1A1 697/4885 |
| US-20130157929-A1 | GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | SLC1A3 2769/4885SLC1A2 4014/4885SLC1A1 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.